文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

一种候选曲妥珠单抗生物类似药对比曲妥珠单抗对ERBB2(HER2)阳性转移性乳腺癌患者总缓解率的影响:一项随机临床试验

Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2017-01-01

这项多中心、双盲、随机、平行组3期等效性研究纳入500例未经治疗的ERBB2阳性转移性乳腺癌患者,按1:1随机接受候选生物类似药或曲妥珠单抗联合紫杉类治疗。第24周总缓解率在生物类似药组为69.6%,曲妥珠单抗组为64.0%,ORR比值(1.09;90%CI 0.974-1.211)和ORR差值(5.53;95%CI -3.08至14.04)均在等效界值内。第48周至肿瘤进展时间、无进展生存和总生存两组间无统计学显著差异。

要点

  • 第24周总缓解率:生物类似药组69.6% vs 曲妥珠单抗组64.0%,ORR比值和差值均在预设等效界值内。
  • 第48周至肿瘤进展时间、无进展生存和总生存两组间无统计学显著差异。
  • 生物类似药组98.6%和曲妥珠单抗组94.7%发生至少1例不良事件,最常见为中性粒细胞减少、周围神经病变和腹泻。

核心结论

  • 在接受紫杉类治疗的ERBB2阳性转移性乳腺癌女性中,使用候选曲妥珠单抗生物类似药对比曲妥珠单抗,第24周总缓解率达到等效。
  • 原文指出需要进一步研究评估安全性和长期临床结局。

研究设计与样本

  • 多中心、双盲、随机、平行组3期等效性研究,2012年12月至2015年8月随机500例患者。
  • 患者按1:1随机接受候选生物类似药(n=230)或曲妥珠单抗(n=228)联合紫杉类。
  • 化疗至少24周,随后单用抗体直至不可接受的毒性作用或疾病进展。
  • 意向治疗人群458例女性(平均[SD]年龄53.6[11.11]岁),安全性人群493例女性。

主要发现

  • 第24周总缓解率:生物类似药组69.6%(95%CI 63.62%-75.51%)vs 曲妥珠单抗组64.0%(95%CI 57.81%-70.26%)。
  • ORR比值(生物类似药/曲妥珠单抗)1.09(90%CI 0.974-1.211),ORR差值5.53(95%CI -3.08至14.04),均在等效界值内。
  • 第48周至肿瘤进展时间:生物类似药组41.3% vs 曲妥珠单抗组43.0%,差值-1.7%(95%CI -11.1%至6.9%),无统计学显著差异。
  • 第48周无进展生存:生物类似药组44.3% vs 曲妥珠单抗组44.7%,差值-0.4%(95%CI -9.4%至8.7%),无统计学显著差异。
  • 第48周总生存:生物类似药组89.1% vs 曲妥珠单抗组85.1%,差值4.0%(95%CI -2.1%至10.3%),无统计学显著差异。

关键数值与推荐

  • 主要结局第24周总缓解率定义为完全或部分缓解。
  • 等效界值:ORR比值(生物类似药/曲妥珠单抗)的90%CI为0.81至1.24;ORR差值的95%CI为-15%至15%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出需要进一步研究评估安全性和长期临床结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Treatment with the anti-ERBB2 humanized monoclonal antibody trastuzumab and chemotherapy significantly improves outcome in patients with ERBB2 (HER2)-positive metastatic breast cancer; a clinically effective biosimilar may help increase access to this therapy. OBJECTIVE: To compare the overall response rate and assess the safety of a proposed trastuzumab biosimilar plus a taxane or trastuzumab plus a taxane in patients without prior treatment for ERBB2-positive metastatic breast cancer. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, double-blind, randomized, parallel-group, phase 3 equivalence study in patients with metastatic breast cancer. From December 2012 to August 2015, 500 patients were randomized 1:1 to receive a proposed biosimilar or trastuzumab plus a taxane. Chemotherapy was administered for at least 24 weeks followed by antibody alone until unacceptable toxic effects or disease progression occurred. INTERVENTIONS: Proposed biosimilar (n = 230) or trastuzumab (n = 228) with a taxane. MAIN OUTCOMES AND MEASURES: The primary outcome was week 24 overall response rate (ORR) defined as complete or partial response. Equivalence boundaries were 0.81 to 1.24 with a 90% CI for ORR ratio (proposed biosimilar/trastuzumab) and -15% to 15% with a 95% CI for ORR difference. Secondary outcome measures included time to tumor progression, progression-free and overall survival at week 48, and adverse events. RESULTS: Among 500 women randomized, the intention-to-treat population included 458 women (mean [SD] age, 53.6 [11.11] years) and the safety population included 493 women. The ORR was 69.6% (95% CI, 63.62%-75.51%) for the proposed biosimilar vs 64.0% (95% CI, 57.81%-70.26%) for trastuzumab. The ORR ratio (1.09; 90% CI, 0.974-1.211) and ORR difference (5.53; 95% CI, -3.08 to 14.04) were within the equivalence boundaries. At week 48, there was no statistically significant difference with the proposed biosimilar vs trastuzumab for time to tumor progression (41.3% vs 43.0%; -1.7%; 95% CI, -11.1% to 6.9%), progression-free survival (44.3% vs 44.7%; -0.4%; 95% CI, -9.4% to 8.7%), or overall survival (89.1% vs 85.1%; 4.0%; 95% CI, -2.1% to 10.3%). In the proposed biosimilar and trastuzumab groups, 239 (98.6%) and 233 (94.7%) had at least 1 adverse event, the most common including neutropenia (57.5% vs 53.3%), peripheral neuropathy (23.1% vs 24.8%), and diarrhea (20.6% vs 20.7%). CONCLUSIONS AND RELEVANCE: Among women with ERBB2-positive metastatic breast cancer receiving taxanes, the use of a proposed trastuzumab biosimilar compared with trastuzumab resulted in an equivalent overall response rate at 24 weeks. Further study is needed to assess safety and long-term clinical outcome. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02472964; EudraCT Identifier: 2011-001965-42.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Rugo HS, Barve A, Waller CF, et al. Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial. JAMA. 2017. PMID: 27918780. doi:10.1001/jama.2016.18305

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。